Bicara Therapeutics Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Gross Margin | — | — | — | — |
| Operating Expenses | ||||
| Research & Development | — | — | $63.6M | $30.6M |
| SG&A Expense | — | $30.5M | $18.8M | $9.3M |
| Operating Income | — | $-155.6M | $-82.4M | $-39.9M |
| Operating Margin | — | — | — | — |
| Interest Expense | — | — | — | — |
| Pretax Income | — | $-137.7M | $-67.8M | $-52.0M |
| Income Tax Expense | — | $217.0K | $187.0K | $5.0K |
| Net Income | — | $-138.0M | $-68.0M | $-52.0M |
| Net Margin | — | — | — | — |
| EPS (Basic) | — | $-2.52 | $-1.35 | $-1.03 |
| EPS (Diluted) | — | $-2.52 | $-1.35 | $-1.03 |
| Shares Outstanding (Basic) | 65.5M | 54.68B | 50.42B | 50.47B |
| Shares Outstanding (Diluted) | 65.5M | 54.68B | 50.42B | 50.47B |
| Dividends Per Share | — | — | — | — |